Analysts expect that IntelliPharmaCeutics Intl Inc (NASDAQ:IPCI) (TSE:I) will post ($0.08) earnings per share (EPS) for the current quarter, Zacks reports. Two analysts have provided estimates for IntelliPharmaCeutics Intl’s earnings. The lowest EPS estimate is ($0.10) and the highest is ($0.05). IntelliPharmaCeutics Intl posted earnings of ($0.14) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 42.9%. The business is expected to report its next earnings report on Friday, February 9th.
On average, analysts expect that IntelliPharmaCeutics Intl will report full-year earnings of ($0.28) per share for the current financial year, with EPS estimates ranging from ($0.31) to ($0.24). For the next financial year, analysts forecast that the business will post earnings of ($0.17) per share, with EPS estimates ranging from ($0.32) to ($0.01). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that cover IntelliPharmaCeutics Intl.
IPCI has been the subject of a number of analyst reports. Zacks Investment Research downgraded IntelliPharmaCeutics Intl from a “hold” rating to a “sell” rating in a report on Wednesday, December 20th. Mackie raised IntelliPharmaCeutics Intl to a “hold” rating and boosted their price target for the company from $1.00 to $3.10 in a report on Tuesday, September 26th. One research analyst has rated the stock with a sell rating, three have given a hold rating and one has assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $2.37.
Shares of IntelliPharmaCeutics Intl (IPCI) opened at $0.79 on Friday. The company has a market capitalization of $27.23, a P/E ratio of -2.32 and a beta of 0.99. IntelliPharmaCeutics Intl has a 52-week low of $0.70 and a 52-week high of $3.12.
A hedge fund recently raised its stake in IntelliPharmaCeutics Intl stock. Advisor Group Inc. lifted its holdings in shares of IntelliPharmaCeutics Intl Inc (NASDAQ:IPCI) (TSE:I) by 57.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 47,409 shares of the company’s stock after buying an additional 17,342 shares during the quarter. Advisor Group Inc. owned approximately 0.16% of IntelliPharmaCeutics Intl worth $100,000 as of its most recent SEC filing. Institutional investors own 3.78% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “IntelliPharmaCeutics Intl Inc (IPCI) Expected to Announce Earnings of -$0.08 Per Share” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://www.dispatchtribunal.com/2018/01/12/intellipharmaceutics-intl-inc-ipci-expected-to-announce-earnings-of-0-08-per-share.html.
About IntelliPharmaCeutics Intl
Intellipharmaceutics International Inc is a Canada-based pharmaceutical company engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals.
Get a free copy of the Zacks research report on IntelliPharmaCeutics Intl (IPCI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for IntelliPharmaCeutics Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntelliPharmaCeutics Intl and related companies with MarketBeat.com's FREE daily email newsletter.